Analysts’ Weekly Ratings Updates for Sensei Biotherapeutics (SNSE)

Several brokerages have updated their recommendations and price targets on shares of Sensei Biotherapeutics (NASDAQ: SNSE) in the last few weeks:

• 6/11/2026 – Sensei Biotherapeutics is now covered by BTIG Research. They set a “buy” rating and a $55.00 price target on the stock.
• 6/4/2026 – Sensei Biotherapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 5/29/2026 – Sensei Biotherapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 5/28/2026 – Sensei Biotherapeutics was given a new $50.00 price target by Loop Capital.
• 5/22/2026 – Sensei Biotherapeutics is now covered by Citigroup Inc.. They set a “buy” rating and a $55.00 price target on the stock.
• 5/16/2026 – Sensei Biotherapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/24/2026 – Sensei Biotherapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/21/2026 – Sensei Biotherapeutics was upgraded by Zacks Research to “hold”.
• 4/20/2026 – Sensei Biotherapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $50.00 price target on the stock.

Insiders Place Their Bets

In other news, major shareholder James Peyer sold 25,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the completion of the transaction, the insider owned 130,142 shares in the company, valued at $2,605,442.84. This trade represents a 16.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Millennium Management Llc purchased 15,321 shares of the company’s stock in a transaction dated Friday, March 27th. The stock was purchased at an average price of $26.61 per share, with a total value of $407,691.81. Following the transaction, the insider owned 142,360 shares of the company’s stock, valued at approximately $3,788,199.60. This represents a 12.06% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 46,980 shares of company stock valued at $1,341,669 and sold 48,067 shares valued at $1,204,939. Company insiders own 7.00% of the company’s stock.

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.